Re:Cognition Health is enrolling volunteers to participate in two studies.
The LUCIDITY Study (Phase III)
This clinical research study aims to evaluate an investigational drug in men and women with early Alzheimer’s disease (AD). Currently, a limited number of approved treatments help with the symptoms of AD, but do not stop the disease from progressing. By reducing the build-up of ‘tau tangles’ in the brain, the main driver of AD, researchers believe that this investigational drug could help slow disease progression and enhance quality of life for people with AD.
You or a loved one may be able to participate in the LUCIDITY study if you/they:
- Are under 90 years of age
- Are experiencing memory loss or changes, or have been diagnosed with:
- MCI (Mild Cognitive Impairment), or
- Probable or Early Alzheimer’s disease, or
- Mild/Moderate Alzheimer’s disease
- Have a study partner who can assist with study participation
The GAIN Study (Phase II Study)
– A Revolutionary New Approach to Understanding Alzheimer’s
The GAIN Trial is based on the growing body of scientiﬁc evidence that the bacteria P. gingivalis, commonly associated with gum disease, can infect the brain and cause Alzheimer’s disease. COR388 is an investigational drug designed to inactivate toxic proteins released by the bacteria and stop or slow further damage to healthy brain cells. A study of COR388 in a small group of Alzheimer’s patients has shown promise in improving memory. GAIN is a clinical trial evaluating whether an investigational oral drug is safe and can halt the progression of Alzheimer’s disease by reducing the damage caused by bacteria in the brain.
You or a loved one may be eligible for the study if you:
- Are 55 to 80 years old
- Have been diagnosed with mild to moderate Alzheimer’s disease
- Have a caregiver or family member who will attend study visits, report on daily activities and oversee you taking medication
Our team of Brain and Mind Experts at Re:Cognition Health are dedicated to research and are focused on paving the way for a future without Alzheimer’s disease. With every study undertaken we come closer to finding out more about Alzheimer’s disease and finding new treatments.
To register interest to participate in a clinical trial visit: